PMID- 23385613
OWN - NLM
STAT- MEDLINE
DCOM- 20130709
LR  - 20130206
IS  - 1531-7048 (Electronic)
IS  - 1065-6251 (Linking)
VI  - 20
IP  - 2
DP  - 2013 Mar
TI  - Expanded indications for allogeneic stem cell transplantation in patients with 
      myeloid malignancies.
PG  - 115-22
LID - 10.1097/MOH.0b013e32835dd84a [doi]
AB  - PURPOSE OF REVIEW: Hematopoietic stem cell transplantation (SCT) can be curative 
      for myeloid malignancies such as acute myeloid leukemia (AML). Advancements in 
      human leukocyte antigen (HLA) typing and supportive care have improved the 
      risk-benefit ratio for SCT, expanding its indications. RECENT FINDINGS: 
      Allogeneic SCT is an established treatment for AML with intermediate-risk and 
      high-risk cytogenetics in first complete remission (CR1), from matched related 
      donors (MRDs). Similar survival benefits are seen for AML in CR1 with unfavorable 
      cytogenetics using matched unrelated donors (URDs). Molecular characterization 
      has delineated patients with AML at higher risk with normal cytogenetics [e.g., 
      FLT3-internal tandem duplication (ITD)+]. The outcomes of allogeneic SCT are 
      comparable in patients with therapy-related or de-novo AML when adjusted for 
      disease status and cytogenetics. In patients lacking a MRD, the majority will 
      have a suitable alternative using an URD, umbilical cord blood, or 
      haploidentical-related donors; outcomes are either comparable or relatively 
      acceptable compared to a matched sibling donor. Comorbidity indices aid in 
      identifying elderly and debilitated patients who may benefit from SCT; the 
      application of SCT has been further increased by reduced-intensity conditioning 
      regimens. SUMMARY: Allogeneic SCT may be extended to almost all patients with 
      AML, and integration of toxicity and relapse risks will determine the best 
      approach for allogeneic SCT in the future.
FAU - Liu, Hongtao
AU  - Liu H
AD  - Section of Hematology/Oncology, University of Chicago, Chicago, Illinois 60637, 
      USA.
FAU - Stock, Wendy
AU  - Stock W
FAU - Bishop, Michael R
AU  - Bishop MR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
SB  - IM
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - Stem Cell Transplantation/*methods
MH  - Tissue Donors
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Homologous
EDAT- 2013/02/07 06:00
MHDA- 2013/07/10 06:00
CRDT- 2013/02/07 06:00
PHST- 2013/02/07 06:00 [entrez]
PHST- 2013/02/07 06:00 [pubmed]
PHST- 2013/07/10 06:00 [medline]
AID - 00062752-201303000-00007 [pii]
AID - 10.1097/MOH.0b013e32835dd84a [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2013 Mar;20(2):115-22. doi: 10.1097/MOH.0b013e32835dd84a.